拯救脓毒症运动:感染与血液净化治疗的研究方向
拯救脓毒症运动研究委员会采用改良德尔菲法,从26个脓毒症与脓毒性休克研究优先事项中,针对感染相关问题及部分辅助治疗问题生成扩展综述。由6名工作组成员分别负责6个问题:经验性抗生素联合治疗、抗菌药物药代动力学/药效学优化、脓毒症诱导免疫抑制所致病毒再激活的抗病毒治疗、快速诊断检测的临床应用、无急性呼吸窘迫综合征的脓毒症患者的肺保护性通气作用、以及如何确定血液净化疗法(如内毒素吸附、细胞因子吸附、血浆置换)的疗效。综述经小组编辑并加入联合主席意见,旨在提供现有证据并突出不确定领域和未来方向。
要点
- 研究委员会针对感染与血液净化治疗提出6个具体研究问题,涵盖抗生素联合治疗、药代动力学优化、抗病毒治疗、快速诊断、肺保护性通气及血液净化疗效评估。
- 经验性抗生素联合治疗是否用于脓毒症或脓毒性休克是待回答的研究问题之一。
- 抗菌药物药代动力学与药效学优化对脓毒症患者结局的影响是待回答的研究问题之一。
- 脓毒症诱导免疫抑制导致的病毒再激活是否应抗病毒治疗是待回答的研究问题之一。
- 如何确定血液净化疗法(内毒素吸附、细胞因子吸附、血浆置换)的疗效是待回答的研究问题之一。
研究设计与关键结果
- 采用改良德尔菲法,拯救脓毒症运动研究委员会近期发布了26个脓毒症与脓毒性休克研究优先事项。
- 工作组成员针对所有感染问题及部分辅助治疗问题生成扩展综述,每个问题由6名工作组成员之一负责。
- 综述经小组整体编辑并加入委员会联合主席意见,最终涉及6个问题:经验性抗生素联合治疗、抗菌药物药代动力学/药效学优化、病毒再激活抗病毒治疗、快速诊断检测、无ARDS脓毒症患者的肺保护性通气、血液净化疗法疗效评估。
证据类型、等级与局限
- 证据类型:指南/共识(拯救脓毒症运动研究委员会报告)。
- 局限:原文未报告局限性。
指南或共识出处
- 拯救脓毒症运动(Surviving Sepsis Campaign)研究委员会报告,发表于Crit Care Explor。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「对床旁实践的改变」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Patients with infection can develop sepsis, and their mortality can be high. An important aspect in the treatment of sepsis is adequate management of the infection.
DATA SOURCES: Using a modified Delphi approach, the Surviving Sepsis Campaign research committee recently published a series of 26 priorities for sepsis and septic shock.
STUDY SELECTION: Task force members with specific expertise were tasked with generating expanded reviews for all infection questions and a subset of adjunctive therapy questions from the larger list of sepsis priorities. Each question was addressed by one of the six task force members.
DATA EXTRACTION: In-depth reviews were then edited by the group as a whole, with added input from the committee cochairs.
DATA SYNTHESIS: Six questions were addressed: 1) should empiric antibiotic combination therapy be used in sepsis or septic shock? 2) does optimization of antimicrobial pharmacokinetics and pharmacodynamics impact patient outcomes in sepsis? 3) should viral reactivation resulting from sepsis-induced immunosuppression be treated with antiviral therapy in critically ill septic patients? 4) should rapid diagnostic tests be implemented in clinical practice? 5) what is the role of lung-protective ventilation in sepsis patients without acute respiratory distress syndrome? and 6) how do we determine the efficacy of "blood purification" therapies such as endotoxin absorbers, cytokine absorbers, and plasmapheresis.
CONCLUSIONS: The research committee members for the Surviving Sepsis Campaign aimed to explore research questions in order to provide existing evidence and highlight areas of uncertainty and future directions.
参考来源
- Martin-Loeches I, Nunnally ME, Hellman J, et al. Surviving Sepsis Campaign: Research Opportunities for Infection and Blood Purification Therapies. Crit Care Explor. 2021. PMID: 34514420. doi:10.1097/CCE.0000000000000511
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。